Personalized therapy on the horizon for squamous cell carcinoma of the lung

Han Sang Kim, Tetsuya Mitsudomi, Ross A. Soo, ByoungChul Cho

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Squamous cell carcinoma (SQCC) of the lung is the second-largest subtype of non-small cell lung cancer (NSCLC), causing an estimated 400,000 deaths per year worldwide. Recent developments in cancer genome sequencing technology expanded our knowledge of driver mutations, which were identified as novel candidates for targeted therapy in various cancers. Successful targeted treatments for lung adenocarcinoma, NSCLC's primary subtype, with EGFR mutation or ALK fusion are clinically available, and a clinical trial of personalized targeted therapy in patients with lung adenocarcinoma is underway by the Lung Cancer Mutation Consortium. Although there are targeted treatments for lung adenocarcinoma, no personalized therapies currently exist for SQCC. Recently, comprehensive genomic characterization of lung SQCC using massively parallel sequencing has enabled us to identify several potential driver mutations/signaling pathways. These are FGFR1 amplifications, PI3KCA mutations, PTEN mutations/deletions, PDGFRA amplifications/mutations, and DDR2 mutations. The march toward personalized therapy may have taken a step forward with the discovery of these potential biomarkers for the treatment of SQCC of the lung.This article reviewed the current knowledge of genomic landscape of lung SQCC and summarized ongoing clinical trials of targeted agents for lung SQCC. Also, we will suggest several other actionable mutations with matching drugs that should be investigated in future clinical trials for the personalized treatment of lung SQCC.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalLung Cancer
Volume80
Issue number3
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Squamous Cell Carcinoma
Lung
Mutation
Clinical Trials
Therapeutics
High-Throughput Nucleotide Sequencing
Sequence Deletion
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Neoplasms
Biomarkers
Genome
Technology
Pharmaceutical Preparations
Adenocarcinoma of lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Kim, Han Sang ; Mitsudomi, Tetsuya ; Soo, Ross A. ; Cho, ByoungChul. / Personalized therapy on the horizon for squamous cell carcinoma of the lung. In: Lung Cancer. 2013 ; Vol. 80, No. 3. pp. 249-255.
@article{d33c9e9485af44798cbd56d4af5ace92,
title = "Personalized therapy on the horizon for squamous cell carcinoma of the lung",
abstract = "Squamous cell carcinoma (SQCC) of the lung is the second-largest subtype of non-small cell lung cancer (NSCLC), causing an estimated 400,000 deaths per year worldwide. Recent developments in cancer genome sequencing technology expanded our knowledge of driver mutations, which were identified as novel candidates for targeted therapy in various cancers. Successful targeted treatments for lung adenocarcinoma, NSCLC's primary subtype, with EGFR mutation or ALK fusion are clinically available, and a clinical trial of personalized targeted therapy in patients with lung adenocarcinoma is underway by the Lung Cancer Mutation Consortium. Although there are targeted treatments for lung adenocarcinoma, no personalized therapies currently exist for SQCC. Recently, comprehensive genomic characterization of lung SQCC using massively parallel sequencing has enabled us to identify several potential driver mutations/signaling pathways. These are FGFR1 amplifications, PI3KCA mutations, PTEN mutations/deletions, PDGFRA amplifications/mutations, and DDR2 mutations. The march toward personalized therapy may have taken a step forward with the discovery of these potential biomarkers for the treatment of SQCC of the lung.This article reviewed the current knowledge of genomic landscape of lung SQCC and summarized ongoing clinical trials of targeted agents for lung SQCC. Also, we will suggest several other actionable mutations with matching drugs that should be investigated in future clinical trials for the personalized treatment of lung SQCC.",
author = "Kim, {Han Sang} and Tetsuya Mitsudomi and Soo, {Ross A.} and ByoungChul Cho",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2013.02.015",
language = "English",
volume = "80",
pages = "249--255",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Personalized therapy on the horizon for squamous cell carcinoma of the lung. / Kim, Han Sang; Mitsudomi, Tetsuya; Soo, Ross A.; Cho, ByoungChul.

In: Lung Cancer, Vol. 80, No. 3, 01.06.2013, p. 249-255.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Personalized therapy on the horizon for squamous cell carcinoma of the lung

AU - Kim, Han Sang

AU - Mitsudomi, Tetsuya

AU - Soo, Ross A.

AU - Cho, ByoungChul

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Squamous cell carcinoma (SQCC) of the lung is the second-largest subtype of non-small cell lung cancer (NSCLC), causing an estimated 400,000 deaths per year worldwide. Recent developments in cancer genome sequencing technology expanded our knowledge of driver mutations, which were identified as novel candidates for targeted therapy in various cancers. Successful targeted treatments for lung adenocarcinoma, NSCLC's primary subtype, with EGFR mutation or ALK fusion are clinically available, and a clinical trial of personalized targeted therapy in patients with lung adenocarcinoma is underway by the Lung Cancer Mutation Consortium. Although there are targeted treatments for lung adenocarcinoma, no personalized therapies currently exist for SQCC. Recently, comprehensive genomic characterization of lung SQCC using massively parallel sequencing has enabled us to identify several potential driver mutations/signaling pathways. These are FGFR1 amplifications, PI3KCA mutations, PTEN mutations/deletions, PDGFRA amplifications/mutations, and DDR2 mutations. The march toward personalized therapy may have taken a step forward with the discovery of these potential biomarkers for the treatment of SQCC of the lung.This article reviewed the current knowledge of genomic landscape of lung SQCC and summarized ongoing clinical trials of targeted agents for lung SQCC. Also, we will suggest several other actionable mutations with matching drugs that should be investigated in future clinical trials for the personalized treatment of lung SQCC.

AB - Squamous cell carcinoma (SQCC) of the lung is the second-largest subtype of non-small cell lung cancer (NSCLC), causing an estimated 400,000 deaths per year worldwide. Recent developments in cancer genome sequencing technology expanded our knowledge of driver mutations, which were identified as novel candidates for targeted therapy in various cancers. Successful targeted treatments for lung adenocarcinoma, NSCLC's primary subtype, with EGFR mutation or ALK fusion are clinically available, and a clinical trial of personalized targeted therapy in patients with lung adenocarcinoma is underway by the Lung Cancer Mutation Consortium. Although there are targeted treatments for lung adenocarcinoma, no personalized therapies currently exist for SQCC. Recently, comprehensive genomic characterization of lung SQCC using massively parallel sequencing has enabled us to identify several potential driver mutations/signaling pathways. These are FGFR1 amplifications, PI3KCA mutations, PTEN mutations/deletions, PDGFRA amplifications/mutations, and DDR2 mutations. The march toward personalized therapy may have taken a step forward with the discovery of these potential biomarkers for the treatment of SQCC of the lung.This article reviewed the current knowledge of genomic landscape of lung SQCC and summarized ongoing clinical trials of targeted agents for lung SQCC. Also, we will suggest several other actionable mutations with matching drugs that should be investigated in future clinical trials for the personalized treatment of lung SQCC.

UR - http://www.scopus.com/inward/record.url?scp=84877156527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877156527&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.02.015

DO - 10.1016/j.lungcan.2013.02.015

M3 - Review article

C2 - 23489560

AN - SCOPUS:84877156527

VL - 80

SP - 249

EP - 255

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -